A recent analysis of pooled nine cardiovascular and renal outcome clinical trials conducted in patients with and without diabetes revealed 21% relative risk reduction of AF in patients treated with SGLT2 inhibitors as compared to placebo [81]. The gene discussed is SLC5A2; the disease is diabetes mellitus.